158 related articles for article (PubMed ID: 35850637)
1. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
2. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
[No Abstract] [Full Text] [Related]
3. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
5. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Guo W; Lin Y; Hu S; Shen Y
Clin Ther; 2023 Oct; 45(10):973-976. PubMed ID: 37599165
[TBL] [Abstract][Full Text] [Related]
6. Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study.
Chan IS; Hsu TF; Shih YC; Chang YH; Wang PH; Chen YJ
Int J Gynaecol Obstet; 2023 Jun; 161(3):751-759. PubMed ID: 36527263
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Osuga Y; Watanabe M; Hagino A
J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
Matsushima T; Akira S; Yoneyama K; Takeshita T
Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Fujimoto-Okabe H; Hagino A
Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
[TBL] [Abstract][Full Text] [Related]
10. Long-term dienogest administration in patients with symptomatic adenomyosis.
Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
[TBL] [Abstract][Full Text] [Related]
11. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Matsubara S; Kawaguchi R; Akinishi M; Nagayasu M; Iwai K; Niiro E; Yamada Y; Tanase Y; Kobayashi H
Sci Rep; 2019 Nov; 9(1):17654. PubMed ID: 31776404
[TBL] [Abstract][Full Text] [Related]
12. A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis.
Ota I; Taniguchi F; Ota Y; Nagata H; Wada I; Nakaso T; Ikebuchi A; Sato E; Azuma Y; Harada T
Reprod Med Biol; 2021 Oct; 20(4):427-434. PubMed ID: 34646070
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest.
Takagi H; Takakura M; Sasagawa T
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):852-857. PubMed ID: 38008504
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments.
Kobayashi H
Gynecol Obstet Invest; 2023; 88(2):71-80. PubMed ID: 36682346
[TBL] [Abstract][Full Text] [Related]
17. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Ota K; Takahashi T; Shiraishi S; Mizunuma H
J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
[TBL] [Abstract][Full Text] [Related]
18. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Xue J; Li L; Li F; Li N; Li T; Li C
J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
[TBL] [Abstract][Full Text] [Related]
19. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
20. Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial.
Sharma S; RoyChoudhury S; Bhattacharya MP; Hazra S; Majhi AK; Oswal KC; Chattopadhyay R
Reprod Biomed Online; 2023 Jul; 47(1):84-93. PubMed ID: 37149412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
